Skip to content

Aspirin for the Enhancement of Trophoblastic Invasion in Women With Abnormal Uterine Artery Doppler at 11-14 Weeks of Gestation

Aspirin for the Enhancement of Trophoblastic Invasion in Women With Abnormal Uterine Artery Doppler at 11-14 Weeks of Gestation

Status
Completed
Phases
Phase 2
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01616615
Acronym
ASAP
Enrollment
190
Registered
2012-06-12
Start date
2012-09-30
Completion date
2015-04-30
Last updated
2015-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Placental Insufficiency

Brief summary

To establish wether a prophylactic intervention from first trimester with low-dose of aspirin improves trophoblastic invasion evaluated at third trimester in women defined as high-risk by abnormal uterine artery Doppler at first trimester

Interventions

DRUGAspirin

150 mg/day oral use

DRUGplacebo

1 capsule / day oral use

Sponsors

Sara Varea
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Caregiver, Investigator)

Eligibility

Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients over 18 years old attending for routine ultrasound at first trimester of pregnancy between 11 and 14 weeks of gestation (Crown-to rump length 45-48mm) * Single gestation * Mean pulsatility index of the uterine arteries above the 95th percentile for our population

Exclusion criteria

* Pre-existing hypertension, renal or cardiovascular disease * previous history of pre-eclampsia * Pregestational diabetes * Systemic lupus Erythematosus * Gastric ulcer * Acetylsalicylic acid or lactose hypersensitivity * Bleeding disorders * Fetal disorders (including chromosomal abnormalities) * Administration of low molecular weight heparin * Concomitant treatment with aspirin

Design outcomes

Primary

MeasureTime frame
Uterine artery mean pulsatilityat 28 weeks of gestation

Secondary

MeasureTime frameDescription
Severe preeclampsiaat deliverySevere preeclampsia defined as: preeclampsia criteria + DBP\> = 110 mmHg, proteinuria\> 5g/24h, oligouria (\<400 ml/24h), neurological symptoms (brain or visual), acute pulmonary edema (gasometric and radiological criteria), persistent epigastric pain, abnormal liver function (AST or Alanine aminotransferase(ALT)\> 70 IU), analytical signs of hemolysis (LDH\> 700 U / L) and / or thrombocytopenia (\<100.000/ml).
Intrauterine Growth Retardationat deliveryIntrauterine Growth Retardation: birth weight below the 10th percentile of our population + pulsatility index in umbilical artery in the third trimester (on two separate occasions \>48h)above the 95th percentile.
Significant neonatal morbidityat deliverySignificant neonatal morbidity (convulsions, intraventricular hemorrhage\> grade III, periventricular leukomalacia, hypoxic-ischemic encephalopathy, abnormal electroencephalogram, necrotizing enterocolitis, acute renal failure (serum creatinine\> 1.5 mg / dl) or heart failure (requiring inotropic agents
Pre-eclampsiadeliverypre-eclampsia defined as: diastolic blood pressure (DBP)\> = 90 mmHg) or systolic (SBP)\> = 140 mmHg on two separated determinations (\> 4h) with proteinuria\> 300 mg/24 h -Gestational age at debut of preeclampsia
Neonatal acidosisat deliveryNeonatal acidosis (arterial pH \<7.10 + Base excess(BE)\> 12 milliequivalent (mEq) / L)
Perinatal mortality28 days post partumPerinatal mortality (\> 22 weeks gestation, \<28 days postpartum)
Days in the Neonatal Intensive Care Unit28 days post partum
number of cesareanat deliveryEmergent cesarean section due to fetal wellbeing loss Birth weight

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026